Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Dec 10, 2024, 07:30 ET Patent covers compositions and methods of use of drug formulation for Zabalafin Hydrogel ANNAPOLIS, Md., Dec. 10, 2024 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and…
Alphyn Biologics Announces Peer-Reviewed Paper Published in Journal of Drugs in Dermatology NEWS PROVIDED BY Alphyn Biologics Nov 01, 2024, 07:30 ET Paper highlights Zabalafin Hydrogel’s potential as a single topical atopic dermatitis therapy that impacts the Staphylococcus aureus component and treats all other disease symptoms across severity levels ANNAPOLIS, Md., Nov. 1, 2024 /PRNewswire/…
International Society of Atopic Dermatitis Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin NEWS PROVIDED BY Alphyn Biologics October 26, 2024, 19:30 ET N432_Neal-KOLLER_Itch-Reduction-and-Quality-of-Life-Improvement-in-AD-for-First-Human-Use-of-Zabalfin CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
Healio: Plant-based topical improves itch, quality of life among patients with atopic dermatitis by Gabrielle M. Grasso NEWS PROVIDED BY Alphyn Biologics October 8, 2024 Zabalafin hydrogel clinically improved itch and quality of life among pediatric and adult patients with atopic dermatitis, according to interim results presented at the European Academy of Dermatology and Venerology…
2024 European Association of Dermatology and Venerology (EADV) Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin Hydrogel NEWS PROVIDED BY Alphyn Biologics September 28, 2024, 19:30 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195